ARID1A and colorectal carcinoma: Patients enrolled in CALGB/SWOG 80405, a randomized phase III study evaluating the efficacy of chemotherapy plus cetuximab vs. chemotherapy plus bevacizumab in first-line CRC, who had ARID1A mutations at baseline, had poorer clinical outcomes with cetuximab compared to bevacizumab.